Covid-19

covid-19

View Covid research bulletins from the Library

NIHR Portfolio Studies - open to recruitment

ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections [COVID-19]
Principal Investigator: Prof. Anil Hormis
Sponsor: University of Oxford
This study will provide rapid, coordinated clinical investigation of patients with confirmed COVID-19 infection. It will look at how the virus reproduces and is excreted by the body, how the body responds to infection and treatment over time and how the immune system responds.

RECOVERY Trial: Randomised Evaluation of COVID-19 Therapy
Principal Investigator: Prof. Anil Hormis
Sponsor: University of Oxford
This international clinical trial aims to identify treatments that may be beneficial for people hospitalised with suspected or confirmed COVID-19.

REMAP-CAP: Randomised, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia
Principal Investigator: Prof. Anil Hormis
Sponsor: University Medical Centre Utrecht / Intensive Care National Audit & Research Centre (ICNARC)
The broad objective of this REMAP is, over time, to determine and continuously update the optimal set of treatments for community-acquired pneumonia. This study will use a study design known as a REMAP, a Randomised, Embedded, Multifactorial, Adaptive Platform trial.

In Follow-up (Recruitment ended):

COV-COMPARE Immunogenicity of vaccine VLA2001 compared to AZD1222
Principal Investigator: Prof. Anil Hormis
Sponsor: Valneva Austria GmbH
This is a multicentre, randomised, observer blind, active-controlled, superiority study to compare the immunogenicity of VLA2001 to AZD1222 in terms of GMT.

COASPIRE: COVID-19 anti-inflammatory specific immunomodulation and recovery enhancing
Principal Investigator: Prof. Anil Hormis
Sponsor: SLA Pharma and KD Swiss GmbH
A randomised, double-blind, placebo controlled study of Eicosapentaenoic Acid (EPA-FFA) gastro-resistant capsules to treat hospitalised subjects with confirmed SARS-CoV-2